{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:46:01Z","timestamp":1790660761992,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>In obese patients receiving durable left ventricular assist devices (LVADs), obesity increases device-related morbidity and may limit access to heart transplantation, while the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains undefined. We performed a retrospective propensity-matched cohort study using the TriNetX US Collaborative Network of adults with obesity who underwent durable LVAD implantation in the United States between 2016 and 2024. Patients with documented GLP-1 RA exposure before implantation were matched 1:1 to nonusers on demographics and baseline comorbidities. The primary outcome was all-cause mortality; secondary outcomes included driveline infection, device malfunction, sepsis, bleeding complications, transplant listing, and heart transplantation at 1 and 3 years. Among 527 obese LVAD recipients, 231 had documented preimplant exposure. After matching, 141 patients were analyzed in each group. At 1 year, exposed patients had a lower hazard of driveline infection. At 3 years, nonusers had higher all-cause mortality, whereas exposed patients had higher rates of transplant listing and heart transplantation. Documented preimplant GLP-1 RA exposure was associated with improved longer-term survival, fewer driveline infections, and greater progression to transplant-related outcomes. These findings are observational and hypothesis-generating but support prospective evaluation in selected LVAD recipients.<\/jats:p>","DOI":"10.1097\/mat.0000000000002804","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:00:48Z","timestamp":1784916048000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8289-1369","authenticated-orcid":false,"given":"Aabha","family":"Divya","sequence":"first","affiliation":[{"name":"Division of Cardiothoracic Surgery, Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-4989","authenticated-orcid":false,"given":"Niti","family":"Dalal","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-2697","authenticated-orcid":false,"given":"Yilin","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-5268","authenticated-orcid":false,"given":"Manreet","family":"Kanwar","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-5903","authenticated-orcid":false,"given":"Pedro","family":"Catarino","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Alessandro","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.21037\/jtd.2017.10.52","article-title":"The impact of extreme obesity on outcomes after left ventricular assist device implantation.","volume":"9","author":"Yost","year":"2017","journal-title":"J Thorac Dis"},{"issue":"12, Part 2","key":"R2-20260724","first-page":"102303","article-title":"Rising trends in obesity and heart failure: related mortality in the United States, 1999-2024.","volume":"4","author":"Sajid","year":"2025","journal-title":"JACC: Advances"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cardfail.2019.10.001","article-title":"Impact of obesity on ventricular assist device outcomes.","volume":"26","author":"Jaiswal","year":"2020","journal-title":"J Card Fail"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pcad.2023.05.003","article-title":"Heart failure and obesity: the latest pandemic.","volume":"78","author":"Aryee","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.15420\/ecr.2025.37","article-title":"Targeting obesity for heart failure.","volume":"20","author":"Morris","year":"2025","journal-title":"Eur Cardiol"},{"key":"R6-20260724","article-title":"Management of obesity in the contemporary LVAD era [published online ahead of print March 5, 2026].","author":"Faria","journal-title":"J Heart Lung Transplant"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1.","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"e029282","DOI":"10.1161\/JAHA.122.029282","article-title":"Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity.","volume":"12","author":"Michos","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity.","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"R13-20260724","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R14-20260724","first-page":"100676","article-title":"All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction.","volume":"60","author":"Vignarajah","year":"2025","journal-title":"Am Heart J Plus"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: special focus on framing the impact of adverse events.","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","article-title":"Two-year outcomes with a magnetically levitated cardiac pump in heart failure.","volume":"378","author":"Mehra","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"e032936","DOI":"10.1161\/JAHA.123.032936","article-title":"Impact of diabetes and glycemia on cardiac improvement and adverse events following mechanical circulatory support.","volume":"13","author":"Kyriakopoulos","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/0391398820906554","article-title":"Weight evolution after implantation of left ventricular assist device: do we need to interfere?","volume":"43","author":"Vandersmissen","year":"2020","journal-title":"Int J Artif Organs"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"e194751","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.15420\/cfr.2025.17","article-title":"Glucagon-like peptide-1 receptor agonists in heart failure: mechanisms, evidence and identifying optimal candidates.","volume":"2025","author":"Abdelhamid","year":"2025","journal-title":"Card Fail Rev"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"R22-20260724","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","journal-title":"N Engl J Med"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1177\/02676591221127651","article-title":"Bleeding and thrombotic complications and their impact on mortality in patients supported with left ventricular assist device for cardiogenic shock.","volume":"38","author":"Bekono-Nessah","year":"2023","journal-title":"Perfusion"},{"key":"R24-20260724","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezaf365","article-title":"Low driveline infection rates in patients with a novel fully magnetically levitated ventricular assist device.","volume":"67","author":"Wang","year":"2025","journal-title":"Eur J Cardiothorac Surg"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10047-024-01482-8","article-title":"Clinical outcomes of modified left ventricular assist device driveline management.","volume":"28","author":"Imaoka","year":"2025","journal-title":"J Artif Organs"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/cid\/ciaa011","article-title":"Epidemiology of left ventricular assist device infections: findings from a large nonregistry cohort.","volume":"72","author":"Blanco-Guzman","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/SLA.0000000000006614","article-title":"Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes.","volume":"281","author":"Aschen","year":"2025","journal-title":"Ann Surg"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"1446468","DOI":"10.3389\/fcvm.2024.1446468","article-title":"Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review.","volume":"11","author":"Skrobucha","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.jhlto.2025.100404","article-title":"Impact of severe obesity on heart transplantation outcomes: a meta-analysis of survival and complications.","volume":"11","author":"Diniz","year":"2026","journal-title":"JHLT Open"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2010.05.016","article-title":"Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.","volume":"56","author":"Uriel","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.athoracsur.2012.02.035","article-title":"Incidence and management of gastrointestinal bleeding with continuous flow assist devices.","volume":"93","author":"Aggarwal","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res Clin Pract"}],"container-title":["ASAIO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000002804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:00:52Z","timestamp":1784916052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000002804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1097\/mat.0000000000002804","relation":{},"ISSN":["1058-2916","1538-943X"],"issn-type":[{"value":"1058-2916","type":"print"},{"value":"1538-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}